Letter: should immunosuppressive therapy be started with adalimumab in Crohn's disease? Authors' reply.

Antibodies, Monoclonal, Humanized/therapeutic use; Crohn Disease/drug therapy; Female; Humans; Immunosuppressive Agents/therapeutic use; Male; Tumor Necrosis Factor-alpha/antagonists & inhibitors

Disciplines :

Gastroenterology & hepatology

Author, co-author :

REENAERS, Catherine

Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie

Belaiche, Jacques ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques

Seidel, Laurence ; Université de Liège - ULiège > Département des sciences de la santé publique > Informatique médicale et biostatistique

Keshav, S.

Travis, S.

Language :

English

Title :

Letter: should immunosuppressive therapy be started with adalimumab in Crohn's disease? Authors' reply.

Publication date :

2013

Journal title :

Alimentary Pharmacology and Therapeutics

ISSN :

0269-2813

eISSN :

1365-2036

Publisher :

Wiley, Oxford, United Kingdom

Volume :

Issue :

Pages :

752-3

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 02 January 2014

Statistics

Number of views

33 (1 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Tursi A,. Letter: should immunosuppressive therapy be started with adalimumab in Crohn's disease? Aliment Pharmacol Ther 2013; 37: 752.
Reenaers C, Louis E, Belaiche J, Seidel L, Keshav S, Travis S,. Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab? Aliment Pharmacol Ther 2012; 36: 1040-8.